DND PharmaTech

DND PharmaTech Current Assets

The Current Assets of DND PharmaTech (347850.KQ) as of Nov 4, 2026 is 201.92 M KRW. In the previous year, Current Assets was 35.89 B KRW — a change of -99.44% (lower).

Current Assets

201.92 MKRW

YoY

-99.44%

Last updated:

Current Assets of DND PharmaTech is 2025 201.92 M KRW. Current Assets of DND PharmaTech was 2024 35.89 B KRW. It decreases by -99.44% lower compared to the previous year.

The DND PharmaTech Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2021
1.28 M KRW
Jan 1, 2022
25.94 B KRW
Jan 1, 2023
17.37 B KRW
Jan 1, 2024
35.89 B KRW
Jan 1, 2025
201.92 M KRW
The DND PharmaTech Current Assets history
YEARCurrent AssetsYoY
201.92 MKRW-99.44%
35.89 BKRW+106.57%
17.37 BKRW-33.04%
25.94 BKRW+2.03 M%
1.28 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DND PharmaTech Stock analysis

What does DND PharmaTech do? DND PharmaTech Inc generates revenue primarily through its research and development activities focused on metabolic disease, neurodegenerative, and fibrotic diseases. The company develops therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis as part of its product pipeline. Clinical-stage biotech companies like DND PharmaTech typically secure funding through partnerships, grants, and potential future licensing agreements with pharmaceutical firms. The target segments include pharmaceutical companies seeking innovative drug candidates and healthcare providers interested in new treatment options for complex conditions. The company's product pipeline targets indications such as metabolic disease, neurodegenerative, and fibrotic diseases. Its research focuses on therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis. DND PharmaTech operates as a clinical-stage biotech firm, meaning it is developing drugs but has not yet commercialized them. The primary buyers of its R&D services and potential future products would be pharmaceutical companies looking to expand their portfolios with new therapies. DND PharmaTech Inc's business model centers on developing innovative treatments for high-need medical conditions. The firm's focus on metabolic disease, neurodegenerative, and fibrotic diseases positions it to address significant unmet medical needs. Its pipeline includes therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis, which are areas with growing market demand. The company's clinical-stage status indicates it is still in the development phase rather than commercial production. DND PharmaTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DND PharmaTech stock

Current Assets of DND PharmaTech is 201.92 M KRW in 2025.

Current Assets of DND PharmaTech changed from 35.89 B KRW to 201.92 M KRW, representing a -99.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets DND PharmaTech since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's DND PharmaTech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — DND PharmaTech

All Key Metrics — DND PharmaTech